Sanofi-aventis U.S. has acquired commercial rights to Oforta (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug, from biotechnology company Antisoma. Oforta is currently approved in the U.S. for use as a second-line therapy to treat adults with B-cell CLL. “We are extremely pleased to add Oforta to our existing oncology portfolio, and believe it represents an exciting opportunity for Sanofi-aventis U.S.,” said John Harrington, vice ...